MULEVACLIN

Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis

Coordinatore	ETNA BIOTECH SRL    more  Organization address address: STRADA VINCENZO LANCIA 57 city: CATANIA postcode: 95100 contact info Titolo: Mr. Nome: Antonio Cognome: Di Mauro Email: send email Telefono: +39 0952500276 Fax: +39 0952500276
Nazionalità Coordinatore	Italy [IT]
Totale costo	7˙442˙193 €
EC contributo	5˙475˙364 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-11-01   -   2018-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ETNA BIOTECH SRL  Organization address address: STRADA VINCENZO LANCIA 57 city: CATANIA postcode: 95100 contact info Titolo: Mr. Nome: Antonio Cognome: Di Mauro Email: send email Telefono: +39 0952500276 Fax: +39 0952500276	IT (CATANIA)	coordinator	1˙284˙750.00
2	AMVAC AG  Organization address address: METALLSTRASSE 4 city: ZUG postcode: 6300 contact info Titolo: Ms. Nome: Marie Christine Cognome: Kopkow Email: send email Telefono: +41 417253230 Fax: +41 417253239	CH (ZUG)	participant	1˙608˙500.00
3	SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT  Organization address address: SOCINSTRASSE 57 city: Basel postcode: CH-4002 contact info Titolo: Prof. Nome: Gerd Cognome: Pluschke Email: send email Telefono: +41 612848235 Fax: +41 61 2848101	CH (Basel)	participant	1˙173˙750.00
4	INSTITUTO DE SALUD CARLOS III  Organization address address: CALLE SINESIO DELGADO 4-6 city: MADRID postcode: 28029 contact info Titolo: Dr. Nome: Javier Cognome: Moreno Email: send email Telefono: 34918223771 Fax: 345097034	ES (MADRID)	participant	684˙000.00
5	INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR - IBMC  Organization address address: RUA DO CAMPO ALEGRE 823 city: PORTO postcode: 4150 180 contact info Titolo: Dr. Nome: Claudia Cognome: Ferreira Email: send email Telefono: +351 226074900 Fax: +351 226099157	PT (PORTO)	participant	300˙000.00
6	UNIVERSIDAD AUTONOMA DE MADRID  Organization address address: CALLE EINSTEIN, CIUDAD UNIV CANTOBLANCO RECTORADO 3 city: MADRID postcode: 28049 contact info Titolo: Ms. Nome: Mª Carmen Cognome: Puerta Email: send email Telefono: 34914978479 Fax: 34914975269	ES (MADRID)	participant	154˙400.00
7	ISTITUTO SUPERIORE DI SANITA  Organization address address: Viale Regina Elena 299 city: ROMA postcode: 161 contact info Titolo: Dr. Nome: Rosa Cognome: Martoccia Email: send email Telefono: +39 06 4990 2688 Fax: +39 06 4990 3007	IT (ROMA)	participant	151˙840.00
8	MEDITOX S.R.O  Organization address address: POD ZAMKEM 279 city: KONAROVICE postcode: 28125 contact info Titolo: Dr. Nome: Martin Cognome: Slais Email: send email Telefono: 420313000000 Fax: 420313000000	CZ (KONAROVICE)	participant	118˙124.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the burden caused by many of the 17 diseases that affect more than 1billion people worldwide can be effectively controlled and, in many cases, eliminated or even eradicated. Leishmaniasis caused by Leishmania spp is one of them and poses a grave health risk to an estimated 350 million people across the world. Among the three clinical patterns of Leishmaniasis (cutaneous, mucocutaneous, and visceral), Visceral Leishmaniasis (VL), also known as kala azar is the most severe in terms of symptoms and clinical complications. If left untreated, the disease can have a fatality rate as high as 100%.Only few drugs are available in the foreseeable future for treating patients from this disease. The development of a human vaccine against Leishmania is an achievable goal.In endemic areas, the majority of infected persons do not develop clinical symptoms and past infection leads to robust immunity against reinfection. In our approach, we mimic a natural infection cycle of Leishmania, by introducing the recombinant protein LJM11 from the sand fly saliva and two other components of Leishmania infantum based on well proven effective recombinant proteins from Leishmania: KMP11 and a recombinant fusion protein SMT-NH. These components will be formulated with a strong TLR4 agonist, already tested in humans, to enhance and modulate the immune response. This innovative vaccine will be tested at the Swiss Tropical and Public Health Institute, which already has experience in conducting clinical trials with Leishmania vaccines. The phase I/II clinical trial will be immunologically monitored by experienced institutions from EU and US. A European SME would have most of the benefits of this project: it would allow to further develop a vaccine against this neglected disease and increase the possibility to out-license this vaccine for commercialization.'